News | November 04, 2007

Boston Scientific Highlights Stentplus Patient Compliance Program at AHA

November 5, 2007 – Boston Scientific Corp. highlighted at the American Heart Association conference its new Stentplus Patient Success Program, which provides tools designed for a cardiology team to assist drug-eluting stent patients—regardless of stent brand—to comply with dual anti-platelet therapy.

The primary goal of the program is to help improve patient adherence and patient outcomes through educational tools and assistance in identifying financial resources.

Three primary factors, according to the program, contribute to patient noncompliance with dual anti-platelet therapy. The first is education as patient recall of information received during physician visits is generally no more than 50 percent. Forgetfulness is a contributing factor to noncompliance is that patients frequently forget to take their medication each day as prescribed. Finally, financial challenges associated with paying for prescription drugs.

The Stentplus Program offers educational materials, including DVD; personalized medication reminders; information about financial assistance programs; and Stentplus.com for more patient information and resources for family members and caregivers.

For more information: www.bostonscientific.com


Related Content

News | Stents Drug Eluting

October 31, 2023 — SMT (Sahajanand Medical Technologies), a leading medical device company in India, focused on ...

Home October 31, 2023
Home
News | Stents Drug Eluting

October 10, 2023 — Elixir Medical, a developer of innovative cardiovascular technologies, announced it will present ...

Home October 10, 2023
Home
News | Stents Drug Eluting

July 13, 2023 — Elixir Medical, a developer of breakthrough cardiovascular technologies, announced enrollment completion ...

Home July 13, 2023
Home
News | Stents Drug Eluting

July 12, 2023 — In a late breaking trial session during EuroPCR 2023 in Paris, on behalf of the HOST-IDEA study ...

Home July 12, 2023
Home
News | Stents Drug Eluting

May 25, 2023 — First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic ...

Home May 25, 2023
Home
News | Stents Drug Eluting

January 2, 2023 — The U.S. Food and Drug Administration (FDA) has approved the BioFreedom Drug Coated Coronary Stent ...

Home January 02, 2023
Home
News | Stents Drug Eluting

December 23, 2022 — According to Coherent Market Insights, the global Drug Eluting Stents market is estimated to be ...

Home December 23, 2022
Home
News | Stents Drug Eluting

June 2, 2022 — Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced print ...

Home June 02, 2022
Home
News | Stents Drug Eluting

February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced ...

Home February 16, 2022
Home
News | Stents Drug Eluting

January 26, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific's Synergy Megatron Drug ...

Home January 26, 2021
Home
Subscribe Now